chufangao/CTO huggingface dataset:
Clinical trial NCT04520022: Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB
Official title: Single Center, Single Group Assignment, Open Label Trial to Assess Safety and Effectiveness of Intravenous Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With Recessive Dystrophic Epidermolysis Bullosa
Sponsor: Gangnam Severance Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-13
Primary completion date: 2020-01-10
Completion date: 2020-01-10
Clinical trial NCT04021264: The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
Official title: The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Inability to enroll participants.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-01
Primary completion date: 2022-01-01
Completion date: 2022-01-01
Clinical trial NCT03225716: A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Official title: A Phase 1/2 Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision to end follow-up early
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-10-20
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03616912: A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Acronym: SLE-BRAVE I
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.
Enrollment: 830.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-08-02
Primary completion date: 2021-11-01
Completion date: 2022-03-09
Baseline population: All randomized participants who receive at least one dose of study drug. One investigational site with seven participants was excluded from analysis due to confirmed misconduct.
Limitations and caveats: One investigational site with seven participants was excluded from analysis due to confirmed misconduct.~Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03523117: Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
Official title: A Multicenter, Randomized, Active-Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia
Sponsor: American Regent, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-31
Primary completion date: 2020-12-22
Completion date: 2021-01-29
Plan to share individual participant data: NO
Clinical trial NCT03448978: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Official title: Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
Sponsor: Cartesian Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Phase 1 enrollment completed. Further clinical development terminated
Enrollment: 32.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-08
Primary completion date: 2021-04-19
Completion date: 2021-06-03
Plan to share individual participant data: NO
Clinical trial NCT03172936: Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Official title: A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 106.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-08
Primary completion date: 2020-12-18
Completion date: 2020-12-18
Plan to share individual participant data: NO
Clinical trial NCT03898661: Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures
Official title: Local Injection of Collagenase Clostridium Histolyticum (XiapexR) for Refractory Iatrogenic Esophageal Strictures: an Open-label Pilot Study
Sponsor: University Hospital, Ghent (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: unexpected serious adverse event
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-29
Primary completion date: 2020-06-30
Completion date: 2021-01-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02504268: Effects of Abatacept in Patients With Early Rheumatoid Arthritis
Official title: A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive
Acronym: AVERT-2
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 994.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-09-03
Primary completion date: 2017-01-16
Completion date: 2020-03-19
Clinical trial NCT04504370: Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
Official title: A Phase III, Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
Acronym: PB119
Sponsor: PegBio Co., Ltd. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 273.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-27
Primary completion date: 2022-03-30
Completion date: 2022-11-28
Plan to share individual participant data: NO
Clinical trial NCT04456049: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
Official title: COVID_ENZA Trial: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
Sponsor: Ente Ospedaliero Cantonale, Bellinzona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-24
Primary completion date: 2021-06-09
Completion date: 2021-06-09
Clinical trial NCT03361319: Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma
Official title: A Phase I Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma
Acronym: N3
Sponsor: Royal Marsden NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawal of financial support from funder
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-07-31
Primary completion date: 2023-07-31
Completion date: 2023-07-31
Plan to share individual participant data: NO
Clinical trial NCT05233436: PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Official title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study terminated based on internal business considerations and was not based on safety reasons
Enrollment: 21.0 (ACTUAL)
Number of arms: 8.0
Start date: 2022-02-24
Primary completion date: 2023-10-16
Completion date: 2023-10-16
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03635983: A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Official title: A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 783.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-21
Primary completion date: 2021-11-19
Completion date: 2024-03-19
Clinical trial NCT04847674: A Study to Test if TEV-53275 is Effective in Relieving Asthma
Official title: A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Stopped for strategic reasons
Enrollment: 97.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-04
Primary completion date: 2022-04-28
Completion date: 2022-04-28
Baseline population: The intent-to-treat (ITT) analysis set included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request
Clinical trial NCT04220632: A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Official title: An Open Label, Multicenter, Phase I/II Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Adverse events of the first patient
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-18
Primary completion date: 2020-10-10
Completion date: 2020-10-10
Clinical trial NCT03400033: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
Official title: A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 407.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-05
Primary completion date: 2020-06-19
Completion date: 2020-06-19
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03416335: A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Official title: A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Sponsor: Sumitomo Pharma America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision to terminate the development of the program due to changing landscape.
Enrollment: 36.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-01
Primary completion date: 2022-12-20
Completion date: 2022-12-20
Limitations and caveats: The sponsor made the decision to terminate the study on August 2022 with all patients removed from treatment and follow-up by December 2022. Consistent with Food and Drug Administration and International Council for Harmonisation guidance on the content for abbreviated and synoptic CSRs, only safety data are analyzed and reported.
Clinical trial NCT01740427: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Official title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 666.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-02-22
Primary completion date: 2016-02-26
Completion date: 2023-11-09
Baseline population: The intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04327986: Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Official title: A Phase I/II Study of the Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study closed to accrual due to the worsening risk: benefit ratio for participants receiving bintrafusp alfa (M7824).
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-06-15
Primary completion date: 2022-01-18
Completion date: 2022-02-03
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to database of Genotypes and Phenotypes (dbGaP).
IPD time frame: Genomic data are available once genomic data are uploaded per protocol genomic data sharing (GDS) plan for as long as database is active.
IPD access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI).~Genomic data are made available via database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Clinical trial NCT02971683: Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
Official title: A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 149.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-04
Primary completion date: 2020-07-27
Completion date: 2022-08-02
Clinical trial NCT02124902: Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Official title: A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient funding/staff
Enrollment: 148.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-07
Primary completion date: 2021-11-10
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02876003: Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
Official title: An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With PSMA Positive Recurrent or Progressive Glioblastoma
Sponsor: GenSpera, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: This study has been withdrawn prior to enrollment.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-30
Primary completion date: 2019-10-31
Completion date: 2020-10-31
Plan to share individual participant data: NO
Clinical trial NCT04044352: H1N1v Virus Challenge Study in Healthy Subjects
Official title: A Controlled Human Infection Study of Influenza A/Bethesda/MM2/H1N1 Virus (A/California/04/2009/H1N1-like) in Healthy Subjects to Assess the Effect of Pre-Existing Immunity on Symptomatic Influenza Virus Infection
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 76.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-22
Primary completion date: 2020-03-02
Completion date: 2020-03-02
Clinical trial NCT02733614: Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD
Official title: A Proof of Concept (POC) Clinical Trial for Post-Traumatic Stress Disorder (PTSD) With a First-In-Class Vasopressin 1a Receptor Antagonist (SRX246)
Sponsor: Azevan Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: funding
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-31
Primary completion date: 2020-10-31
Completion date: 2021-03-31
Plan to share individual participant data: NO
Clinical trial NCT04448899: Ivabradine in Patients With Congestive Heart Failure
Official title: Effects of Ivabradine on Neopterin and NT-Pro BNP in Patients With Congestive Heart Failure
Sponsor: Damanhour University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2021-02-01
Completion date: 2021-02-05
Plan to share individual participant data: NO
Clinical trial NCT03707418: Bivalirudin vs Heparin in ECMO Patients
Official title: A Randomized Study Comparing Bivalirudin vs Heparin in Patients With Extracorporeal Membrane Oxygenator (ECMO) Support
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: unable to secure funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02490878: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Official title: Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Sponsor: Alliance for Clinical Trials in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2019-02-01
Completion date: 2022-12-15
Clinical trial NCT03436953: A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The program was not initiated nor were any patients ever enrolled. The investigations detailed in the submitted protocol were incorporated into another program.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-31
Primary completion date: 2020-09-30
Completion date: 2020-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05361083: First-in-human Evaluation of [18F]CETO
Official title: Studies of 18F-CETO as a Tracer for Adrenal PET Diagnostics
Sponsor: Uppsala University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-01
Primary completion date: 2021-04-01
Completion date: 2022-02-28
Plan to share individual participant data: NO